Ebglyss (lebrikizumab) is an IL-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adult and pediatric patients ages 12 and older who weigh ≥40 kg. It is administered by subcutaneous injection with a dosing regimen that can be tailored to patient needs.
Ebglyss selectively binds to IL-13, a key cytokine implicated in the pathophysiology of AD. By binding to IL-13 with high affinity and slow dissociation, Ebglyss prevents the formation of the IL-4R⍺/IL-13R⍺1 receptor complex and inhibits downstream IL-13 signaling. This targeted mechanism addresses the inflammation and skin barrier dysfunction central to AD.
The label for Ebgyss specifically mentions the following adverse reactions (≥1%): conjunctivitis, injection site reactions, and herpes zoster.
Ebglyss can be effectively incorporated into treatment plans for patients with moderate-to-severe AD who have not achieved adequate control with topical therapies or other systemic agents. It can be used as monotherapy or alongside topical treatments, providing flexibility in addressing both acute and chronic disease management.
Ebglyss stands out for its highly specific inhibition of IL-13, offering a more focused approach compared to agents that target multiple cytokines. Its favorable safety profile and targeted action make it suitable for long-term use in eligible patients. Ebglyss has demonstrated substantial efficacy in improving disease severity and patient quality of life, making it a valuable option in the expanding AD treatment landscape.